A COPD drug from China draws $115M in venture funding
A COPD drug from China draws $115M in venture funding
Biopharm & Life Sciences Intelligence
The definitive intelligence hub for biopharmaceuticals, clinical developments, stock market indicators, and biotechnology careers.
Latest Intelligence Updates
Alnylam plunges as earnings deliver 'one-two punch'
Alnylam plunges as earnings deliver 'one-two punch'
An AstraZeneca-Bristol Myers megamerger? Wall Street isn't thrilled.
An AstraZeneca-Bristol Myers megamerger? Wall Street isn't thrilled.
Attovia adds to biotech IPO momentum with $289M offering
Attovia adds to biotech IPO momentum with $289M offering
BioMarin axes $270M asset after missing phase 3 endpoint
BioMarin axes $270M asset after missing phase 3 endpoint
BioNTech brings in Sobi CEO—Chutes & Ladders
BioNTech brings in Sobi CEO—Chutes & Ladders
BioNTech taps Sobi executive Oelkers as its next CEO
BioNTech taps Sobi executive Oelkers as its next CEO
Drug patents protect pharma profits. Track when they'll expire.
Drug patents protect pharma profits. Track when they'll expire.
Erica Schwartz confirmed as next CDC director
Erica Schwartz confirmed as next CDC director
FDA approves Moderna's mRNA flu vaccine
FDA approves Moderna's mRNA flu vaccine
FDA Issues Emergency Use Authorization for Drug to Prevent New World Screwworm in Multiple Species, Including Sheep, Cattle, Goats, and Swine
FDA Issues Emergency Use Authorization for Drug to Prevent New World Screwworm in Multiple Species, Including Sheep, Cattle, Goats, and Swine
Fresenius Kabi recalls morphine lot that could lead to death
Fresenius Kabi recalls morphine lot that could lead to death
Intellia finds genetic suspect for liver safety signals with ATTR gene therapy
Intellia finds genetic suspect for liver safety signals with ATTR gene therapy
J&J pharma leader to retire; Krystal slumps on gene therapy miss
J&J pharma leader to retire; Krystal slumps on gene therapy miss
Lilly climbs, Novo falls as obesity drug battle intensifies
Lilly climbs, Novo falls as obesity drug battle intensifies
Novo Nordisk makes Omnicom agency of record for US media buying
Novo Nordisk makes Omnicom agency of record for US media buying
Novo Nordisk’s CFO reflects on ‘pressure’ to drive growth
Novo Nordisk’s CFO reflects on ‘pressure’ to drive growth
Novo setback casts doubt on a new way to treat heart disease
Novo setback casts doubt on a new way to treat heart disease
Pfizer expands multibillion-dollar cost-cutting plan
Pfizer expands multibillion-dollar cost-cutting plan
Replimune melanoma drug wins support of FDA panel
Replimune melanoma drug wins support of FDA panel
Replimune to ride wave of physician support to launch advanced melanoma therapy
Replimune to ride wave of physician support to launch advanced melanoma therapy
Resilience and Lilly invest $750M to boost Cincinnati drug production
Resilience and Lilly invest $750M to boost Cincinnati drug production
Sanofi to 'rebuild trust' with Regeneron; Apnimed adds to string of 'upsized' biotech IPOs
Sanofi to 'rebuild trust' with Regeneron; Apnimed adds to string of 'upsized' biotech IPOs
Supernus, Indivior merge to beef up brain drug portfolio
Supernus, Indivior merge to beef up brain drug portfolio
Takeda, Daiichi, Astellas and more—Fierce Pharma Asia
Takeda, Daiichi, Astellas and more—Fierce Pharma Asia
Actimed recovers cachexia rights, ending $126M Faraday deal
Actimed Therapeutics has regained rights to its cachexia drug after terminating its $126 million deal with Faraday Pharmaceuticals.
BioVie stock halves on Parkinson's phase 2 readout
BioVie's stock fell by half after a Phase 2 readout in Parkinson's disease failed to impress, with the company pointing to a composite endpoint analysis.
Braveheart charges to $382.5M IPO to fund Hengrui cardio drug
Braveheart Bio has priced an upsized $382.5 million IPO to fund a Hengrui-licensed cardiometabolic drug, extending the biotech IPO streak.
Co-Diagnostics Submits FDA 510(k) Premarket Notification for Upper Respiratory Point-of-Care Test
Co-Diagnostics has submitted a dual 510(k) premarket notification, with a concurrent CLIA waiver request, to the FDA for its Co-Dx PCR Flu A/B & RSV upper respiratory multiplex test on the Co-Dx PCR Pro instrument.
Context ends bispecific trial to extend runway deeper into 2027
Context Therapeutics is discontinuing its bispecific antibody trial to conserve cash and extend its runway deeper into 2027.
Double shot of Vistagen's anxiety nasal spray misses in ph. 2
Vistagen's anxiety nasal spray failed to beat placebo in two Phase 2 trials, another setback for the company's pipeline.
FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma
FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma
LifeMine revived by $188M fundraise backed by Gates and Bezos
LifeMine revived by $188M fundraise backed by Gates and Bezos
PacBio CEO steps down as Q2 loss widens
Pacific Biosciences' CEO is stepping down as the sequencing company reported a wider second-quarter loss.
Sanofi asked to change Dupixent ads after Galderma challenge
Sanofi has been asked to change its Dupixent advertising after a challenge from Galderma over the campaign's claims.
Sanofi pauses mid-stage lung study amid new CEO's 'rigorous portfolio prioritization'
Sanofi has paused a mid-stage chronic lung disease study as new CEO Belen Garijo applies rigorous portfolio prioritization to the pipeline.
Sarepta's new CEO faces critical tests to prove growth
Sarepta's new CEO faces critical tests to prove growth
Tarsus pays $450M for Alkeus and its ph. 3 retinal disease drug
Tarsus Pharmaceuticals is paying $450 million to acquire Alkeus Pharmaceuticals and its Phase 3 Stargardt disease drug, expanding into retinal disease.
Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition
Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition
The next treatment-resistant depression paradigm
The next treatment-resistant depression paradigm
U.S. moves to shut a Kentucky organ donation group, citing safety failures
The U.S. government is moving to shut down a Kentucky organ donation group accused of continuing plans for organ retrieval from some patients who unexpectedly showed signs of life.
US FDA approves first mRNA flu shot from Moderna, includes gallery
US FDA approves first mRNA flu shot from Moderna, includes gallery
VerilyMe, Bausch + Lomb partner up on dry eye education
VerilyMe, Bausch + Lomb partner up on dry eye education
ViiV targets 'future you' in long-acting HIV campaign
ViiV Healthcare is rolling out a new long-acting HIV campaign aimed at 'future you', promoting its long-acting treatment options.
4 potential biotech M&A targets, plus a pretty sure bet from J&J
BioSpace rounds up four biotechs seen as potential M&A targets plus a likely Johnson & Johnson acquisition bet as pharma dealmaking heats up.
5 NextGen winners who went public this year (and which ones are hiring)
Five BioSpace NextGen honorees went public this year; most are looking for biopharma professionals to join their teams.
Amgen's MariTide stands alone after obesity cull while analysts seek more M&A
Amgen discontinued an early-stage obesity candidate, leaving MariTide as its lead obesity asset while analysts push for more M&A.
AstraZeneca, CSPC to form manufacturing joint venture
AstraZeneca and China's CSPC Pharmaceutical Group are forming a biologics manufacturing joint venture.
Attovia's CEO aims to scratch itch opportunity with $289M IPO
Attovia Therapeutics aims to raise $289 million in an IPO to advance three immunology and inflammation drug candidates, including a bid to challenge Dupixent in itch.
Aveva Drug Delivery Systems prevails on appeal, Federal Circuit affirms non-infringement of ZTlido patents
The Federal Circuit affirmed a district court ruling that Aveva Drug Delivery Systems' generic ZTlido product does not infringe Scilex's patents, preparing the company for an imminent launch of its generic product with 180-day exclusivity.
Bespoke gene-editing outfit abandons lead program, cuts 'several' employees
Jennifer Doudna's Aurora Therapeutics is abandoning its lead PKU gene-editing program and cutting 'several' staffers seven months after launching with $16 million in seed financing, citing growing competition in the field.
BioVie shares halve on murky Parkinson’s disease readout
BioVie shares halve on murky Parkinson’s disease readout
Braveheart pumps more life into biotech IPO market with $382M expected debut
Braveheart pumps more life into biotech IPO market with $382M expected debut
Epilepsia Open publishes results of post hoc data analysis of FINTEPLA (fenfluramine) in patients with Lennox-Gastaut syndrome
UCB announced that Epilepsia Open published findings from a post hoc analysis of FINTEPLA (fenfluramine) effectiveness and safety, including dose changes over time, in patients with Lennox-Gastaut syndrome.
Erica Schwartz confirmed as CDC director, filling nearly yearlong vacancy
The Senate has confirmed Erica Schwartz as CDC director, filling a nearly yearlong vacancy at the agency.
FDA Approves First Drug to Treat the Full Range of Narcolepsy Type 1 Symptoms
The FDA has approved the first drug to treat the full range of narcolepsy Type 1 symptoms, including the sudden muscle weakness episodes known as cataplexy.
Gilead looks to upcoming inflammation, cancer catalysts as pressure to diversify mounts
Gilead's inflammation portfolio faces a packed back half of 2026 as the company works to expand beyond its HIV franchise.
LifeMine raises $263M in mission to improve organ transplant aftercare
Organ transplant biotech LifeMine Therapeutics has raised a combined $263 million — a $75 million Series D and an oversubscribed $188 million Series F — to support the clinical program for LIFE-001, under development to prevent organ failure.
Lilly drops another gene therapy trial from $1B Prevail buyout
Eli Lilly is dropping another gene therapy program acquired in its roughly $1 billion Prevail Therapeutics buyout, extending a series of portfolio reductions.
Lilly, FDA retatrutide biologic dispute comes to a head as submission nears
A legal dispute between the FDA and Eli Lilly over whether the obesity candidate retatrutide is a biologic has come to a head as the company's submission nears.
Lilly's $23B Q2 soars over expectations but Foundayo lags Novo's rival oral GLP-1
Eli Lilly delivered a big Q2 earnings beat with 48% revenue growth to $23 billion, though its oral GLP-1 candidate Foundayo trailed Novo Nordisk's rival pill.
Moderna begins first human trial of Bundibugyo Ebola vaccine
Moderna begins first human trial of Bundibugyo Ebola vaccine
Moderna's flu shot crosses FDA finish line, bouncing back from regulatory roadblock
Moderna's mRNA flu shot has won FDA approval, bouncing back after a refusal-to-file letter earlier this year and becoming the first approved mRNA flu vaccine.
MRI is standard for diagnosing prostate cancer in most western countries. But most U.S. men don't get them
Doctors debate whether biopsies are overused at the expense of MRI scans in prostate cancer screening, as most U.S. men don't receive MRIs even though the scans are standard in most western countries.
Narcan maker Emergent axes top R&D post in sweeping restructuring
Emergent BioSolutions is eliminating the role of chief medical officer and head of R&D in a sweeping restructuring that leaves the Narcan maker without a dedicated C-suite R&D leader.
Novo CEO sees innovation as a matter of survival amid pipeline setbacks
Novo Nordisk CEO Maziar Mike Doustdar says the company is focused on building out its pipeline to move past recent clinical roadblocks.
Over 1/3 stay in biopharma jobs for health insurance, poll finds
A poll finds more than one-third of biopharma and biotech professionals stay in their jobs primarily for health insurance benefits.
Reckitt announces U.S. FDA approval of Mucinex 12HR Cold & Fever Multi-Symptom, the first OTC innovation in the cold & flu category in 14 years
Reckitt announced FDA approval of Mucinex 12HR Cold & Fever Multi-Symptom, the first and only FDA-approved OTC cold and flu medication that treats fever, cough, chest congestion and body pain for 12 hours — the company's first new drug approval.
Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms
Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms
Sanofi-backed Expedition lands $115M for ph. 2 COPD trial
Expedition Therapeutics raised $115 million to advance its lead oral DPP1 inhibitor EXPD-101 into a global Phase 2 COPD trial.
Sanofi suspends chronic lung disease phase 2 study
Sanofi suspends chronic lung disease phase 2 study
Takeda’s narcolepsy nod opens orexin doors
Takeda’s narcolepsy nod opens orexin doors
Third time’s the charm for Replimune as melanoma drug earns FDA greenlight
Third time’s the charm for Replimune as melanoma drug earns FDA greenlight
Amgen doesn't think Repatha's sales wins will stop anytime soon
Amgen sees continued momentum for its cholesterol drug Repatha, expecting the cardiology product's sales growth to keep rolling.
Aqua Medical Names Bob Haggerty CEO to Take on Type 2 Diabetes
Aqua Medical named Bob Haggerty as CEO as the company targets type 2 diabetes.
Bayer CEO Anderson sticking out firm's revitalization scheme
Bayer CEO Bill Anderson is staying the course on the company's multi-year turnaround plan, pledging improvement in every quarter.
Ebola kills 1,700 in eastern Congo as the fastest-growing outbreak surges
The Ebola outbreak in eastern Democratic Republic of Congo has now killed 1,700 people, making it the fastest-growing outbreak of the virus on record.
Gilead prevails in yearslong HIV drug innovation case
Gilead prevailed in a yearslong HIV drug innovation lawsuit after the California Supreme Court ruled drugmakers have no duty to innovate.
Icon inks Anthropic deal to deploy Claude into clinical trials
Contract research organization Icon has partnered with Anthropic to deploy its Claude AI assistant across clinical trial operations.
Jazz to withdraw Zepzelca in second-line small cell lung cancer
Jazz Pharmaceuticals will withdraw Zepzelca from the second-line small cell lung cancer setting after a confirmatory trial failure.
J&J innovative medicine chief Jennifer Taubert to retire
Jennifer Taubert, head of Johnson & Johnson's innovative medicine division, is set to retire.
KKR inks $5.7B deal to take medtech manufacturer Integer private
KKR has signed a $5.7 billion deal to take medical device manufacturer Integer Holdings private.
Latigo laces up for $247M IPO to fund rival to Vertex's Journavx
Latigo Biotherapeutics has set terms for a $247 million IPO to fund its non-opioid pain drug rival to Vertex's Journavx.
Lisata axes 72% of workforce following failed merger with Kuva
Lisata Therapeutics is cutting 72% of its staff and suing Kuva after their planned merger fell through.
Lisata lays off 72% of staffers, sues Kuva after merger folds
Lisata Therapeutics is laying off 72% of its staff and suing Kuva Therapeutics after their proposed merger fell apart.
MellingMedical Teams Up with NIDEK USA to Advance Vision Care Technology for Veterans and Beyond
MellingMedical and NIDEK USA are partnering to advance vision care technology for veterans and broader patient populations.
Merck charts long-term path for first PCSK9 pill
The FDA has made Merck's Lipfendra a poster child for its CNPV pilot as Merck charts a long-term path for the first oral PCSK9 pill.
Merck's $10.8B Prometheus deal delivers another win—plus a Phase 2b miss
Merck's $10.8 billion Prometheus acquisition delivered one mid-stage win and one Phase 2b miss in inflammatory disease trials.
More reductions for Pfizer as it tacks on $2.5B in cost savings
Pfizer unveiled an additional $2.5 billion in planned cost savings through 2029 as it continues cutting costs and programs.
New England Biolabs launches Monarch Mag Cell-free RNA (cfRNA) Extraction Kit to enable total cfRNA isolation from biofluids
New England Biolabs launched its Monarch Mag Cell-free RNA (cfRNA) Extraction Kit to enable total cfRNA isolation from biofluids.
NIPRO launches expanded hemodialysis with ELISIO-HX to U.S. providers following FDA clearance
NIPRO is bringing its expanded hemodialysis approach to U.S. providers with the ELISIO-HX medium-cutoff dialyzer following FDA 510(k) clearance.
Pathos inks back-to-back cancer contracts with AstraZeneca, China's Alphamab
AI-enabled oncology biotech Pathos AI signed back-to-back cancer deals with AstraZeneca and China's Alphamab worth up to $2.2 billion.
Pfizer axes ex-Metsera obesity asset and GIPR prospect
Pfizer has dropped an obesity asset it acquired from Metsera along with a GIPR-targeting prospect as part of its portfolio pruning.
Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts, includes gallery
Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts, includes gallery
Pfizer CEO defends $7B bolt-on M&A strategy as peers rush to buy
Pfizer CEO Albert Bourla defended the company's $7 billion bolt-on M&A strategy as peers rush to make larger acquisitions.
5 companies advancing ATTR assets in the wake of Wainua's fail
The Phase 3 failure of AstraZeneca and Ionis Pharmaceuticals' antisense therapy in transthyretin amyloid cardiomyopathy last month left the space reeling. BioSpace looks at five contenders advancing ATTR assets and where they stand.
Amgen says hackers stole patient data in cloud breach
Amgen reports hackers stole company and patient information in a data breach, noticing unauthorized activity affecting data stored on cloud platforms hosted by third-party providers in July.
Ascletis Announces Initiation of Global Phase III for Oral Small Molecule GLP-1, ASC30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule GLP-1/GIP/Amylin Fixed-Dose Combination
Ascletis has initiated a global Phase III program for oral small molecule GLP-1 ASC30, which will enroll approximately 4,600 participants with obesity or overweight, and reported positive preclinical data for its first-in-class oral GLP-1/G
AstraZeneca, Bristol Myers in talks about merger — report
AstraZeneca and Bristol Myers Squibb are in merger talks per the Financial Times; AZ is worth roughly $265B and BMS about $133B, and the talks may not lead to a deal.
Biologics push CMOs/CDMOs to expand sterile fill-finish and prefilled syringe capacity
As biologics, biosimilars and GLP-1s drive demand for sterile drug products, CMOs and CDMOs are investing in fill-finish, lyophilization, inspection and packaging capacity to keep pace with the injectable market.
BioNTech cuts sales forecast on slumping demand for COVID-19 vaccine
BioNTech downgraded its sales forecast amid slumping demand for its COVID-19 vaccine.
BioNTech names Guido Oelkers its new CEO
BioNTech has named Guido Oelkers its new CEO, replacing co-founder Ugur Sahin; Oelkers most recently led Swedish biopharma company Sobi.
BioNTech names Sobi's Guido Oelkers as incoming CEO
BioNTech names Sobi CEO Guido Oelkers as its next chief executive, effective by Feb. 1, 2027, as Uğur Şahin exits and the company refocuses on oncology.
Biotech leaders call for streamlining of INDs as FDA's Trialblazer rolls out
The FDA's new investigational new drug pilot program, part of HHS's broader clinical trial modernization initiatives, has lofty goals to expedite first-in-human trials of novel drugs, but experts say it won't tip the scales alone.
BlossomHill eyes $112M IPO harvest to fund Tagrisso challenger
BlossomHill Therapeutics eyes a $112M IPO to bankroll development of a potential challenger to AstraZeneca's blockbuster EGFR inhibitor Tagrisso.
Curium buys Lantheus for $8B; Sandoz settles price-fixing cases
Curium acquires Lantheus for $102.5/share (~$8B); Sandoz settles price-fixing claims for $478.5M; Latigo eyes a $247M IPO for non-opioid LTG-001; BlossomHill targets a $111M IPO.
FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan
Acurx has received FDA guidance from a July 2026 Type C meeting on ibezapolstat's Phase 3 clinical program, including the potential for a single-Phase 3-trial registration plan and a trial design supporting both treatment and reduction of r
Heart transplant candidates fail if they get too weak. New program tries inpatient prehab
Patients often get weaker waiting in the hospital for heart transplant. A cardiologist had an idea: inpatient prehabilitation.
In a first, Otsuka's Voyxact stabilizes IgAN kidney loss in ph.3
Otsuka's Voyxact stabilized kidney function decline in IgAN patients in a Phase 3 trial, a first for the indication.
Invenio Imaging Announces Completion of Enrollment in Landmark Study of AI-Based Image Analysis for Lung Cancer
Invenio Imaging, a leader in fresh tissue imaging and artificial intelligence, announced completion of patient enrollment in a landmark study of AI-based image analysis for lung cancer.
Lilly and Resilience invest $750M in diabetes and obesity drug device supply
The $750M investment will expand Resilience's US capacity to make the KwikPen device Eli Lilly uses to deliver its injectable diabetes and obesity medicines.
MapLight CEO on what investors missed in the biotech's schizophrenia data
Q&A: MapLight Therapeutics CEO Christopher Kroeger discusses what investors missed in the biotech's schizophrenia trial data.
Michigan reports the first 2 U.S. deaths related to a diarrhea-causing parasite
Michigan has reported the first two U.S. deaths linked to the ongoing cyclospora outbreak, which has surged to record levels this summer.
New study offers additional evidence for the VASCADE MVP XL system's effectiveness in electrophysiology procedures with large bore sheaths
A new study adds evidence for the VASCADE MVP XL system's effectiveness in electrophysiology procedures using large-bore sheaths, per an announcement from Haemonetics.
Novartis' Pluvicto unlocks substantial new patient pool
Novartis' radioligand therapy Pluvicto leaps ahead into earlier manifestations of prostate cancer, unlocking a substantially larger patient pool.
Novo's late-stage IL-6 stumble shakes inflammation space
Novo Nordisk was banking on the inflammatory benefits of its investigational therapy ziltivekimab to improve cardiovascular outcomes. Last week's Phase 3 failure dashed not just the Danish pharma's hopes but those of the broader inflammatio
Pfizer cuts $2.5B more across R&D, manufacturing in ongoing restructure
Pfizer is cutting an additional $2.5 billion across R&D and manufacturing as part of its ongoing restructuring.
Supernus, Indivior to merge and form CNS-focused drugmaker
Supernus and Indivior agree to an all-stock merger creating a $2.2B CNS biopharma led by CEO Jack Khattar, closing Q4 2026.
‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
Work ethic becomes a flashpoint as China's biotech pace quickens
As China's biotech sector accelerates, executives at Sironax, Candid, InduPro and others weigh in on work-ethic gaps with US counterparts.
Apnimed's IPO Bags $192M for What Could Become the First Oral Sleep Apnea Drug
Apnimed's IPO bags $192M for what could become the first oral sleep apnea drug; proceeds will support the regulatory process and launch plans for Oxnimbi.
Attovia's Upsized IPO Brings In $289M to Fund New Kind of Biologic for Immune Disorders
Attovia's Upsized IPO Brings In $289M to Fund New Kind of Biologic for Immune Disorders
HHS Is Reviving Its 340B Rebate Push — And Providers Are None Too Pleased
HHS is reviving its 340B drug discount rebate push, drawing pushback from providers.
KKR nearing deal to buy medical device firm Integer, WSJ reports
KKR nearing deal to buy medical device firm Integer, WSJ reports
Lawmakers seek answers from RFK on Gardasil shot settlement
Lawmakers seek answers from RFK on Gardasil shot settlement
Moderna delays norovirus vaccine trial readout because of too few infections
Moderna is delaying the readout of its norovirus vaccine trial because the study has not yet accumulated enough infections to power the analysis.
Moderna Gets FDA Approval for mRNA Flu Vaccine, But CDC Input Still Uncertain
Moderna Gets FDA Approval for mRNA Flu Vaccine, But CDC Input Still Uncertain
Novo Nordisk rocked by late-stage cardiovascular drug failure
Novo Nordisk's cardiovascular pipeline suffered a late-stage clinical failure, a setback for the company's expansion beyond diabetes and obesity.
Pathos Picks Up Two Cancer Drugs Poised for Clinical Development With AI Agents
Pathos AI picked up two cancer drugs poised for clinical development, applying AI agents to drive the work forward.
QuantHealth Snags $45M to Simulate Clinical Trials Before Patients Ever Enroll
QuantHealth raised $45 million to simulate clinical trials before patients ever enroll, applying AI to drug development.
Skyrizi's momentum defies J&J's rival Icotyde as AbbVie raises full-year sales guidance
AbbVie raised its full-year sales guidance on the strength of Skyrizi, whose momentum is holding up against Johnson & Johnson's rival drug Icotyde.
Supernus and Indivior to Merge, Forming a New CNS-Focused Pharma Company
Supernus Pharmaceuticals and Indivior will merge to form a new CNS-focused pharmaceutical company.
AbbVie shares pressured as Q2 I&I beat falls below investor expectations
AbbVie shares pressured as Q2 I&I beat falls below investor expectations
AbCellera, Vertex partner on next-gen T-cell engagers
AbCellera, Vertex partner on next-gen T-cell engagers
Alnylam absorbs $10.8B blowback after cutting full-year guidance for TTR franchise
Alnylam absorbs $10.8B blowback after cutting full-year guidance for TTR franchise
Alnylam's slump deepens; Q2 earnings roundup; and more
Alnylam's stock slide deepened as the company reported second-quarter earnings, part of a broader biotech Q2 earnings roundup.
Amylyx demystifies post-bariatric hypoglycemia
Amylyx demystifies post-bariatric hypoglycemia
An eye drug biotech banks $118M and stocks its executive suite
An eye drug biotech banks $118M and stocks its executive suite
Apnimed raises $192M IPO for potential 2027 sleep apnea drug launch
Apnimed raises $192M IPO for potential 2027 sleep apnea drug launch
Apnimed’s IPO dream comes true with upsized $192M IPO
Apnimed’s IPO dream comes true with upsized $192M IPO
Brazil, Korea and UEA all targeting biotech ‘emerging economy’
Brazil, Korea and UEA all targeting biotech ‘emerging economy’
Caldera, Vidya add to recent flurry of biotech mergers
Caldera, Vidya add to recent flurry of biotech mergers
Capricor CEO won’t rule out legal action against FDA after negative adcomm
Capricor CEO won’t rule out legal action against FDA after negative adcomm
Capricor Duchenne cell therapy voted down by FDA panel
Capricor Duchenne cell therapy voted down by FDA panel
Chasing Vertex, Latigo reports non-opioid pain drug succeeds in key trial
Chasing Vertex, Latigo reports non-opioid pain drug succeeds in key trial
Daiichi Sankyo flags accounting error; shares tank
Daiichi Sankyo flags accounting error; shares tank
FDA panel endorses broader use of certain peptides
FDA panel endorses broader use of certain peptides
FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer's data
FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer's data
FDA scientists question Capricor data; Legend CEO steps down
FDA scientists question Capricor data; Legend CEO steps down
Federal government could improve infectious disease monitoring, says federal government
Federal government could improve infectious disease monitoring, says federal government
FTC sues Hims & Hers over alleged privacy violations, deceptive billing practices
FTC sues Hims & Hers over alleged privacy violations, deceptive billing practices
GSK prepares for patent cliff with $2.5B cost-cutting plan
GSK prepares for patent cliff with $2.5B cost-cutting plan
HIV resurgence looming as international aid declines
HIV resurgence looming as international aid declines
Ionis' top scientist Frank Bennett to retire; Recursion selects its first AI chief
Ionis' top scientist Frank Bennett to retire; Recursion selects its first AI chief
J&J nabs option to buy 'in vivo' CAR-T maker Sail for nearly $2.6B
J&J nabs option to buy 'in vivo' CAR-T maker Sail for nearly $2.6B
J&J takes $2.58bn option to buy in vivo CAR-T firm Sail
J&J takes $2.58bn option to buy in vivo CAR-T firm Sail
Karyopharm reports Xpovio miss, FDA filing in separate cancers
Karyopharm reports Xpovio miss, FDA filing in separate cancers
Karyopharm shares crater on second Phase 3 flop for Xpovio in endometrial cancer
Karyopharm shares crater on second Phase 3 flop for Xpovio in endometrial cancer
Legend Biotech, Merck, Otsuka—Fierce Pharma Asia
Legend Biotech, Merck, Otsuka—Fierce Pharma Asia
Legend CEO departs without successor in place—Chutes & Ladders
Legend CEO departs without successor in place—Chutes & Ladders
Limb girdle muscular dystrophy patients face a maddening reality
Limb girdle muscular dystrophy patients face a maddening reality
MapLight dives despite positive data for schizophrenia drug
MapLight dives despite positive data for schizophrenia drug
Merck, Wellcome partner with global health group to make Ebola vaccine for clinical trials, includes gallery
Merck, Wellcome partner with global health group to make Ebola vaccine for clinical trials, includes gallery
Moderna beats quarterly revenue estimates ahead of key US flu vaccine decision
Moderna beats quarterly revenue estimates ahead of key US flu vaccine decision
Novo left praying to Artemis and Hermes as CKD trial flops
Novo left praying to Artemis and Hermes as CKD trial flops
Novo’s IL-6 inhibitor fails in cardiovascular Phase 3, plunging shares more than 9%
Novo’s IL-6 inhibitor fails in cardiovascular Phase 3, plunging shares more than 9%
Pharma groups back changes to 340B rebate pilot as earlier version remains stuck in court
Pharmaceutical industry groups are backing revised terms for the 340B drug-pricing rebate pilot while an earlier version of the program remains tied up in litigation.
Psychedelics, peptides and GLP-1s
Psychedelics, peptides and GLP-1s
Ractigen Therapeutics Announces U.S. FDA IND Clearance for First-in-Class saRNA Candidate RAG-1C to Treat Proliferative Vitreoretinopathy
Ractigen Therapeutics Announces U.S. FDA IND Clearance for First-in-Class saRNA Candidate RAG-1C to Treat Proliferative Vitreoretinopathy
Ratio collects $70M for its radiopharmaceutical trials; Vogenx plans $67M IPO
Ratio collects $70M for its radiopharmaceutical trials; Vogenx plans $67M IPO
Regeneron, Sanofi tease potential expanded collaboration for Dupixent follow-ons
Regeneron, Sanofi tease potential expanded collaboration for Dupixent follow-ons
Sanofi drug pipeline worries, Dupixent dependence shake shares
Sanofi drug pipeline worries, Dupixent dependence shake shares
Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO
Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO
Syphilis spreads while researchers contend with federal constraints and a drug shortage
Syphilis spreads while researchers contend with federal constraints and a drug shortage
Trump's pharma tariffs won't kick in Friday because there's no one left to kick
The first round of tariffs on pharmaceutical imports is not starting as planned, with implementation stalling as the agencies tasked with enforcing them remain depleted.
UK patient first in world to get novel lung cancer vaccine
UK patient first in world to get novel lung cancer vaccine
UniQure welcomes possible adcomm for Huntington’s asset as regulatory ‘jitters’ spread through biopharma
UniQure welcomes possible adcomm for Huntington’s asset as regulatory ‘jitters’ spread through biopharma
US judge says Novo Nordisk must face lawsuit over CagriSema
US judge says Novo Nordisk must face lawsuit over CagriSema
We once praised the American Diabetes Association’s courage. How things have changed
We once praised the American Diabetes Association’s courage. How things have changed
With $5.5B sales, AbbVie's Skyrizi matches Humira's best quarter
With $5.5B sales, AbbVie's Skyrizi matches Humira's best quarter
Get In Touch
For partnerships, media inquiries, or general updates, reach out to us:
Email: info@openbionews.com
Phone: 925 394-6606